Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 24 October 2003:
Vol. 302. no. 5645, pp. 588 - 590
DOI: 10.1126/science.302.5645.588
Prev | Table of Contents | Next

News

Preventing Toxicity With a Gene Test

Eliot Marshall

To test or not to test? That is the question clinicians are asking about screening for genes that affect how the body metabolizes drugs.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Dermatology in the Postgenomic Era: Harnessing Human Variation for Personalized Medicine.
A. E. Oro (2008)
Arch Dermatol 144, 389-391
   Full Text »    PDF »
TPMT testing in rheumatology: any better than routine monitoring?.
K. Payne, W. Newman, E. Fargher, K. Tricker, I. N. Bruce, and W. E. R. Ollier (2007)
Rheumatology 46, 727-729
   Full Text »    PDF »
Thiopurines, DNA damage, DNA repair and therapy-related cancer.
P. Karran (2007)
Br. Med. Bull.
   Abstract »    Full Text »    PDF »
Regulatory Perspectives on Pharmacogenomics: A Review of the Literature on Key Issues Faced by the United States Food and Drug Administration.
K. A. Phillips and S. L. Van Bebber (2006)
Med Care Res Rev 63, 301-326
   Abstract »    PDF »
The emergence of epidemiology in the genomics age.
M. J Khoury, R. Millikan, J. Little, and M. Gwinn (2004)
Int. J. Epidemiol. 33, 936-944
   Full Text »    PDF »
Criteria influencing the clinical uptake of pharmacogenomic strategies.
J. Shah (2004)
BMJ 328, 1482-1486
   Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)